Denali Therapeutics (DNLI) Net Cash Flow (2017 - 2026)
Denali Therapeutics (DNLI) posted quarterly Net Cash Flow of $182.3 million for Q1 2026, up 256.5% year-over-year from $51.1 million in Q1 2025, and up 59.4% quarter-over-quarter from $114.4 million in Q4 2025.
Denali Therapeutics (DNLI) Net Cash Flow (2017 - 2026) Analysis & Trends
Denali Therapeutics (DNLI) has reported Net Cash Flow for 10 consecutive years, with $182.3 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Net Cash Flow rose 256.5% year-over-year to $182.3 million; the TTM figure through Mar 2026 stood at $330.7 million (up 15876.67% YoY), while the FY2025 annual figure was $31.9 million, down 33.35% from the prior year.
- Net Cash Flow advanced to $182.3 million in Q1 2026 per DNLI's latest filing, from $114.4 million in the prior quarter.
- Across five years, Net Cash Flow topped out at $182.3 million in Q1 2026 and bottomed at -$188.5 million in Q1 2022.
- Historically, Net Cash Flow has averaged $5.6 million across 5 years, with a median of $16.0 million in 2024.
- Annual changes were most pronounced in 2024 — Net Cash Flow surged 503.37% — and 2025, when it plunged 414.87%.
- Denali Therapeutics' Net Cash Flow stood at $99.4 million in 2022, then sank by 121.03% to -$20.9 million in 2023, then soared by 503.37% to $84.3 million in 2024, then surged by 35.62% to $114.4 million in 2025, then jumped by 59.4% to $182.3 million in 2026.
- Business Quant data shows DNLI's Net Cash Flow at $182.3 million in Q1 2026, $114.4 million in Q4 2025, and -$50.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 374.50 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 407.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 17.81 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 225.59 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -496,000.00 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -37.14 Mn |
| 10 | Denali Therapeutics | 3.90 Bn | 3.90 Bn | 3.51 Mn | -186.10 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -186.10 Mn |
| Jun 30, 2026 | -186.10 Mn |
| Mar 31, 2026 | 182.30 Mn |
| Mar 31, 2026 | 182.30 Mn |
| Dec 31, 2025 | 114.36 Mn |
| Dec 31, 2025 | 114.36 Mn |
| Sep 30, 2025 | -50.24 Mn |
| Sep 30, 2025 | -50.24 Mn |
| Jun 30, 2025 | 84.26 Mn |
| Jun 30, 2025 | 84.26 Mn |
| Mar 31, 2025 | -116.48 Mn |
| Mar 31, 2025 | -116.48 Mn |
| Dec 31, 2024 | 84.32 Mn |
| Dec 31, 2024 | 84.32 Mn |
| Sep 30, 2024 | 15.96 Mn |
| Sep 30, 2024 | 15.96 Mn |
| Jun 30, 2024 | 14.11 Mn |
| Jun 30, 2024 | 14.11 Mn |
| Mar 31, 2024 | -66.53 Mn |
| Mar 31, 2024 | -66.53 Mn |